Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.

Park JH, Kim JY, Choi JH, Park HS, Shin HY, Lee JM, Kim JW, Ko HJ, Chon S, Kim BK, Kim CS, Lim S

International journal of obesity (2005)20 Jan 2021Cited by 32 (Europe PMC)

PMID33473176DOI10.1038/s41366-021-00739-zPepBankPUB-33473176

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanObservational studySafety outcome
Among all participants on liraglutide 3 mg, 27.6% experienced adverse effects.
In plain wordsIn adults with obesity in Korea, about 1 in 4 had a side effect on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableAny adverse effect
Study
n = 769
Outcome group
Adverse events · Whole body
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Participants with adverse effects
27.6%
all participants
Source sentences
Summary
Among all participants, 27.6% experienced adverse effects
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317609
02HumanObservational studySafety outcome
Among all participants on liraglutide 3 mg, 20.8% had nausea.
In plain wordsIn adults with obesity in Korea, about 1 in 5 had nausea on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n = 769
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Participants with nausea
20.8%
all participants
Source sentences
Summary
nausea (20.8%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317610
03HumanObservational studySafety outcome
Among all participants on liraglutide 3 mg, 5.2% had vomiting.
In plain wordsIn adults with obesity in Korea, a small share had vomiting on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableVomiting
Study
n = 769
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Participants with vomiting
5.2%
all participants
Source sentences
Summary
vomiting (5.2%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317611
04HumanObservational studySafety outcome
Among all participants on liraglutide 3 mg, 2.5% had diarrhoea.
In plain wordsIn adults with obesity in Korea, a small share had diarrhoea on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableDiarrhoea
Study
n = 769
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Participants with diarrhoea
2.5%
all participants
Source sentences
Summary
diarrhoea (2.5%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317612
05HumanObservational studySafety outcome
Among all participants on liraglutide 3 mg, 3.6% had skin rash.
In plain wordsIn adults with obesity in Korea, a small share had a skin rash on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableSkin rash
Study
n = 769
Outcome group
Adverse events · Skin and wound
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Participants with skin rash
3.6%
all participants
Source sentences
Summary
skin rash (3.6%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317613
06HumanObservational studyEfficacy outcome
In the 6-month cohort, 52.5% of subjects lost 5% or more of body weight on liraglutide 3 mg.
In plain wordsIn adults with obesity in Korea, about half lost at least 5% of body weight in 6 months of liraglutide.
Peptide
Liraglutide
Outcome
Not applicableAt least 5% weight loss
Study
n = 219
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 6 monthsAs given in this study (human).
Measurements
Responders at least 5% weight loss
52.5%
6-month cohort
Source sentences
Summary
In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317603
07HumanObservational studyEfficacy outcome
In the 6-month cohort, 18.3% of subjects lost 10% or more of body weight on liraglutide 3 mg.
In plain wordsIn adults with obesity in Korea, about 1 in 5 lost at least 10% of body weight in 6 months of liraglutide.
Peptide
Liraglutide
Outcome
Not applicableAt least 10% weight loss
Study
n = 219
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 6 monthsAs given in this study (human).
Measurements
Responders at least 10% weight loss
18.3%
6-month cohort
Source sentences
Summary
In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317604
08HumanObservational studyEfficacy outcome
In adults with obesity in Korea, body weight decreased after starting liraglutide 3 mg, at 2, 4 and 6 months compared with baseline.
In plain wordsIn adults with obesity in Korea, body weight fell after starting liraglutide compared with before treatment. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 2 to 6 monthsAs given in this study (human).
Measurements
Weight change
−2.94 kg
2 months
Weight change
−4.23 kg
4 months
Weight change
−5.14 kg
6 months
Source sentences
Summary
Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m² at 2 months; -4.23 kg and -1.55 kg/m² at 4 months, and -5.14 kg and -1.89 kg/m² at 6 months (all P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317601
09HumanObservational studyEfficacy outcome
In adults with obesity in Korea, BMI decreased after starting liraglutide 3 mg, at 2, 4 and 6 months compared with baseline.
In plain wordsIn adults with obesity in Korea, body mass index fell after starting liraglutide compared with before treatment. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseBMI change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 2 to 6 monthsAs given in this study (human).
Measurements
BMI change
−1.08 kg/m2
2 months
BMI change
−1.55 kg/m2
4 months
BMI change
−1.89 kg/m2
6 months
Source sentences
Summary
Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m² at 2 months; -4.23 kg and -1.55 kg/m² at 4 months, and -5.14 kg and -1.89 kg/m² at 6 months (all P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317602
10HumanObservational studyEfficacy outcome
After 6 months of liraglutide 3 mg, systolic blood pressure decreased significantly.
In plain wordsIn adults with obesity in Korea, systolic blood pressure fell after 6 months of liraglutide. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
3 mg daily · 6 monthsAs given in this study (human).
Measurements
Systolic BP change
−3.9 mmHg
6 months
Source sentences
Summary
After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317605
11HumanObservational studyEfficacy outcome
After 6 months of liraglutide 3 mg, diastolic blood pressure decreased significantly.
In plain wordsIn adults with obesity in Korea, diastolic blood pressure fell after 6 months of liraglutide. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
3 mg daily · 6 monthsAs given in this study (human).
Measurements
Diastolic BP change
−1.93 mmHg
6 months
Source sentences
Summary
After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317606
12HumanObservational studyEfficacy outcome
In those with diabetes mellitus, HbA1c decreased significantly on liraglutide 3 mg.
In plain wordsIn adults with obesity and diabetes in Korea, HbA1c (long-term blood sugar) fell on liraglutide. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseHbA1c in people with diabetes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg dailyAs given in this study (human).
Measurements
HbA1c change
−1.14%
people with diabetes
Source sentences
Summary
In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317607
13HumanObservational studyEfficacy outcome
In those with diabetes mellitus, fasting glucose decreased significantly on liraglutide 3 mg.
In plain wordsIn adults with obesity and diabetes in Korea, fasting blood sugar fell on liraglutide. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose in people with diabetes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Fasting glucose change
−27.8 mg/dl
people with diabetes
Source sentences
Summary
In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317608
14HumanObservational studySafety outcome
Adverse events were a documented reason for stopping liraglutide 3 mg in 4.3% of participants.
In plain wordsIn adults with obesity in Korea, a small share stopped liraglutide because of side effects.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation due to adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Discontinuation due to adverse events
4.3%
participants
Source sentences
Summary
adverse events (4.3%), and high cost (3.1%).
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317614
15HumanObservational studyOther
Lack of effect was a documented reason for stopping liraglutide 3 mg in 4.4% of participants.
In plain wordsIn adults with obesity in Korea, a small share stopped liraglutide because it did not work enough.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation due to lack of effect
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Discontinuation due to lack of effect
4.4%
participants
Source sentences
Summary
lack of effect (4.4%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317615
16HumanObservational studyOther
High cost was a documented reason for stopping liraglutide 3 mg in 3.1% of participants.
In plain wordsIn adults with obesity in Korea, a small share stopped liraglutide because of cost.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation due to high cost
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
3 mg dailyAs given in this study (human).
Measurements
Discontinuation due to high cost
3.1%
participants
Source sentences
Summary
high cost (3.1%)
1 context sentence(design, population, supporting numbers)
Summary · context
People first using liraglutide starting in 2018 were recruited from ten sites in Korea.
Report a problemFND-3347317616

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.